This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Groot, J. W. B. Articles by Hofstra, R. M. W. Search for Related Content PubMed PubMed Citation Articles by de Groot, J. W. B. Articles by Hofstra, R. M. W.

RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors

Departments of Endocrinology (J.W.B.d.G., T.P.L.), Surgical Oncology (J.W.B.d.G., J.T.M.P.), and Genetics (R.M.W.H.), University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands; and Department of Endocrinology (C.J.M.L.), University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands

Correspondence: Address all correspondence and requests for reprints to: R. M. W. Hofstra, Ph.D., Department of Genetics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Postbus 30 001, 9700 RB Groningen. E-mail: r.m.w.hofstra{at}medgen.umcg.nl

The RET gene encodes a receptor tyrosine kinase that is expressed in neural crest-derived cell lineages. The RET receptor plays a crucial role in regulating cell proliferation, migration, differentiation, and survival through embryogenesis. Activating mutations in RET lead to the development of several inherited and noninherited diseases. Germline point mutations are found in the cancer syndromes multiple endocrine neoplasia (MEN) type 2, including MEN 2A and 2B, and familial medullary thyroid carcinoma. These syndromes are autosomal dominantly inherited. The identification of mutations associated with these syndromes has led to genetic testing to identify patients at risk for MEN 2 and familial medullary thyroid carcinoma and subsequent implementation of prophylactic thyroidectomy in mutation carriers. In addition, more than 10 somatic rearrangements of RET have been identified from papillary thyroid carcinomas. These mutations, as those found in MEN 2, induce oncogenic activation of the RET tyrosine kinase domain via different mechanisms, making RET an excellent candidate for the design of molecular targeted therapy. Recently, various kinds of therapeutic approaches, such as tyrosine kinase inhibition, gene therapy with dominant negative RET mutants, monoclonal antibodies against oncogene products, and nuclease-resistant aptamers that recognize and inhibit RET have been developed. The use of these strategies in preclinical models has provided evidence that RET is indeed a potential target for selective cancer therapy. However, a clinically useful therapeutic option for treating patients with RET-associated cancer is still not available.

This article has been cited by other articles:

				M. J. Bugalho, R. Domingues, and A. Borges A Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with Sunitinib Oncologist, November 1, 2009; 14(11): 1083 - 1087. [Abstract] [Full Text] [PDF]

				D Zenaty, Y Aigrain, M Peuchmaur, P Philippe-Chomette, C Baumann, F Cornelis, J P Hugot, D Chevenne, V Barbu, P J Guillausseau, et al. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B Eur. J. Endocrinol., May 1, 2009; 160(5): 807 - 813. [Abstract] [Full Text] [PDF]

				J P. Couto, H Prazeres, P Castro, J Lima, V Maximo, P Soares, and M Sobrinho-Simoes How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer J. Clin. Pathol., May 1, 2009; 62(5): 414 - 421. [Abstract] [Full Text] [PDF]

				D Engelmann, D Koczan, P Ricken, U Rimpler, J Pahnke, Z Li, and B M Putzer Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance Endocr. Relat. Cancer, March 1, 2009; 16(1): 211 - 224. [Abstract] [Full Text] [PDF]

				M. Peppa, E. Boutati, S. Kamakari, V. Pikounis, G. Peros, I. G Panayiotides, T. Economopoulos, S. A Raptis, and D. Hadjidakis Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene Eur. J. Endocrinol., December 1, 2008; 159(6): 767 - 771. [Abstract] [Full Text] [PDF]

				I. Plaza-Menacho, L. Mologni, E. Sala, C. Gambacorti-Passerini, A. I. Magee, T. P. Links, R. M. W. Hofstra, D. Barford, and C. M. Isacke Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting J. Biol. Chem., October 5, 2007; 282(40): 29230 - 29240. [Abstract] [Full Text] [PDF]

				J. W. B. de Groot, B. A. Zonnenberg, P. Q. van Ufford-Mannesse, M. M. de Vries, T. P. Links, C. J. M. Lips, and E. E. Voest A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3466 - 3469. [Abstract] [Full Text] [PDF]

				K. Frank-Raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2007; 157(2): 215 - 220. [Abstract] [Full Text] [PDF]

				I. Plaza-Menacho, T. van der Sluis, H. Hollema, O. Gimm, C. H. C. M. Buys, A. I. Magee, C. M. Isacke, R. M. W. Hofstra, and B. J. L. Eggen Ras/ERK1/2-mediated STAT3 Ser727 Phosphorylation by Familial Medullary Thyroid Carcinoma-associated RET Mutants Induces Full Activation of STAT3 and Is Required for c-fos Promoter Activation, Cell Mitogenicity, and Transformation J. Biol. Chem., March 2, 2007; 282(9): 6415 - 6424. [Abstract] [Full Text] [PDF]